Exagen (XGN) Cost of Revenue (2018 - 2026)

Exagen (XGN) has reported Cost of Revenue for 9 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $7.1 million, up 11.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (up 23.45% YoY), and the FY2025 annual result was $27.8 million, up 23.29% from the prior year.
• Cost of Revenue was $7.1 million for Q1 2026 at Exagen, down from $7.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $7.4 million in Q4 2025 and troughed at $5.2 million in Q4 2024.
• Average Cost of Revenue over 5 years is $6.2 million, with a median of $6.0 million recorded in 2024.
• Year-over-year, Cost of Revenue decreased 10.92% in 2023 and jumped 43.4% in 2025.
• Over 5 years, Cost of Revenue stood at $6.3 million in 2022, then retreated by 10.92% to $5.6 million in 2023, then fell by 7.86% to $5.2 million in 2024, then surged by 43.4% to $7.4 million in 2025, then slipped by 4.36% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $7.1 million in Q1 2026, $7.4 million in Q4 2025, and $7.2 million in Q3 2025.